Ovoca Bio (CDI) (OVB)

Sector:

Pharma and Biotech

 1.15p
   
  • Change Today:
      0.000p
  • 52 Week High: 1.92
  • 52 Week Low: 0.68
  • Currency: UK Pounds
  • Shares Issued: 88.46m
  • Volume: 0
  • Market Cap: £1.02m

Ovoca Bio enrols first patient in sexual desire treatment trial

By Josh White

Date: Friday 29 Jan 2021

LONDON (ShareCast) - (Sharecast News) - Biopharmaceutical company Ovoca Bio said on Friday that the first patient has been enrolled in a phase 2 dose-ranging study assessing 'BP-101', which it described as a novel treatment for premenopausal women with hypoactive sexual desire disorder (HSDD) - a condition characterised by a distressing lack or loss of sexual desire.
The AIM-traded firm said the phase 2 dose-ranging study was being conducted in Australia and New Zealand and would investigate BP-101, administered daily at a range of doses, evaluating the effect of the drug on lack or loss of sexual desire experienced by participating patients.

It said the double-blind placebo-controlled study was expected to enrol 476 patients across 13 sites.

BP-101 is a synthetic peptide administered through a nasal spray, and was being supplied for this study by peptide manufacturers in Switzerland and the UK.

The co-primary objectives of the study would be to evaluate the effect of three different doses of BP-101 and placebo, on sexual desire, as measured by the Female Sexual Function Index (FSFI) desire domain; and, the degree to which a participant was bothered by low sexual desire, as measured by the Female Sexual Distress Scale.

Ovoca Bio said the change in those clinically-relevant and validated endpoints would be assessed between a four week baseline period and after four weeks of daily dosing.

"We are delighted that the first patient has been enrolled in this phase 2 study as we continue towards our goal of establishing the value of BP-101 as a potential treatment for patients around the world suffering from HSDD," said chief executive officer Kirill Golovanov.

"We hope that this study of BP-101, the first to be conducted outside of Russia, will pave the way for the international development of BP-101 in the US and EU."

At 1020 GMT, shares in Ovoca Bio were down 6.54% at 10p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Ovoca Bio (CDI) Market Data

Currency UK Pounds
Share Price 1.15p
Change Today 0.000p
% Change 0.00 %
52 Week High 1.92
52 Week Low 0.68
Volume 0
Shares Issued 88.46m
Market Cap £1.02m

Ovoca Bio (CDI) Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
0.16% above the market average0.16% above the market average0.16% above the market average0.16% above the market average0.16% above the market average
14.89% above the sector average14.89% above the sector average14.89% above the sector average14.89% above the sector average14.89% above the sector average
Value
0.16% above the market average0.16% above the market average0.16% above the market average0.16% above the market average0.16% above the market average
14.89% above the sector average14.89% above the sector average14.89% above the sector average14.89% above the sector average14.89% above the sector average
Income Not Available
Growth Not Available

Ovoca Bio (CDI) Dividends

No dividends found

Trades for --2025

Time Volume / Share Price
0 @ 0.000p

Ovoca Bio (CDI) Key Personnel

CEO Timothy McCutcheon

Top of Page